Arrowhead Pharmaceuticals (ARWR) ARWR Financial Results Summary

Arrowhead Pharmaceuticals (ARWR) Q4 2025 Financial Results Summary

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) released its financial results for the fiscal year ended September 30, 2025, on November 25, 2025. Below is a summary of the key financial metrics and company developments.

Selected Recent Events

• FDA Approval of REDEMPLO:
• Approved as an adjunct to diet for reducing triglycerides in adults with familial chylomicronemia syndrome (FCS).
• Represents the first FDA-approved siRNA medicine for FCS, a condition affecting approximately 6,500 people in the U.S.

• Significant triglyceride reduction of -80% from baseline found in the Phase 3 PALISADE study.

• Pricing and Support Programs:

• A standardized pricing model, One-REDEMPLO, was introduced.

• Launched the Rely On REDEMPLO patient support program, which offers resources and financial assistance to eligible patients.

• Collaboration with Novartis:

• Entered a global licensing agreement for ARO-SNCA, receiving a $200 million upfront payment with potential total payments of up to $2 billion.

• Clinical Trials:

• Filed requests for regulatory clearance for two new clinical trials:

  • ARO-DIMER-PA targeting atherosclerotic cardiovascular disease (ASCVD).
  • ARO-MAPT for tauopathies such as Alzheimer’s disease.

• Milestone Payments:

• Earned $300 million in milestone payments from Sarepta Therapeutics, with part of the payment received in common stock.

• Share Repurchase:

• Conducted a direct stock buyback from Sarepta worth approximately $50 million at a price of $18.79 per share.

• Advancements in Clinical Trials:

• Successfully dosed the first subject in the Phase 3 clinical trial of zodasiran for homozygous familial hypercholesterolemia (HoFH).

• Asset Purchase Agreement with Sanofi:

• A subsidiary, Visirna Therapeutics, signed an agreement with Sanofi for the commercialization of investigational candidates in Greater China, receiving $130 million upfront.

Selected Fiscal 2025 Year-End Financial Results

• Revenue:

• $829,448,000 for FY 2025, a significant increase of 23,345% from $3,551,000 in FY 2024.

• Operating Expenses:

• Research and development expenses of $607,159,000, up 19.93% from $505,870,000 in FY 2024.

• General and administrative expenses increased to $123,943,000, growing by 25.5% from $98,761,000 in FY 2024.

• Operating Income:

• Operating income of $98,346,000, compared to an operating loss of -$601,080,000 in FY 2024.

• Income Before Taxes:

• Income before income taxes of $51,533,000, a turnaround from a loss of -$612,460,000 in the previous year.

• Net Income:

• Net income attributable to Arrowhead Pharmaceuticals was -$1,631,000, improving significantly from a loss of -$599,493,000 in FY 2024.

• Net income per share attributable stood at -$0.01, compared to -$5.00 in FY 2024.

• Financial Position:

• Cash, cash equivalents, and restricted cash totaled $226,548,000, a rise from $102,685,000 in 2024.
• Total cash resources of $919,366,000, compared to $680,961,000 in FY 2024.

• Total assets reached $1,385,295,000, up from $1,139,802,000 in FY 2024.

• Liabilities:

• Total liabilities stood at $881,879,000, a decrease from $948,739,000 in FY 2024.

• Stockholders’ Equity:

• Total stockholders’ equity rose to $503,416,000, compared to $191,063,000 the prior year.

Conclusion

Arrowhead Pharmaceuticals showcased remarkable growth in its financial performance for FY 2025, spearheaded by the FDA approval of REDEMPLO and strategic collaborations, indicating a transformative year for the company as it transitions into a commercial stage. The company did not declare a quarterly dividend in this report.